September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Fenofibrate Suppresses Retinal Pathologic Neovascularization via Inhibiting Cytochrome P450 Epoxygenase 2C Activity
Author Affiliations & Notes
  • Yan Gong
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Zhongjie Fu
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Matthew Edin
    National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States
  • Nicholas Saba
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Thomas Fredrick
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Peyton Morss
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Samuel Burnim
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Steven Meng
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Darryl Zeldin
    National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, United States
  • Lois E H Smith
    Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Yan Gong, None; Zhongjie Fu, None; Matthew Edin, None; Nicholas Saba, None; Thomas Fredrick, None; Peyton Morss, None; Samuel Burnim, None; Steven Meng, None; Darryl Zeldin, None; Lois Smith, None
  • Footnotes
    Support  NIH/NEI (R01 EY022275, R01 EY017017, P01 HD18655), Lowy Medical Foundation, European Commission FP7 (305485) (LEHS), NIH/NEI (R01 EY024963) (JC)
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4529. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yan Gong, Zhongjie Fu, Matthew Edin, Nicholas Saba, Thomas Fredrick, Peyton Morss, Samuel Burnim, Steven Meng, Darryl Zeldin, Lois E H Smith; Fenofibrate Suppresses Retinal Pathologic Neovascularization via Inhibiting Cytochrome P450 Epoxygenase 2C Activity. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4529.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Fenofibrate reduces cholesterol levels via proliferator-activated receptor alpha (PPARα) activation in diabetic patients with cardiovascular disease and has a direct effect on retinopathy through activation of PPARα in animal studies. In a subanalysis of the effect of fenofibrate on retinopathy in both the Fenofibrate Intervention and Event Lowering in Diabetes study and the Action to Control Cardiovascular Risk in Diabetes Eye trial with ~10,000 type 2 diabetic patients either there was ~40% reduction in progression of retinopathy with fenofibrate treatment independent of its lipid lowering effect. Because fenofibrate is a potent inhibitor of Cytochrome P450 epoxygenase 2C8 (CYP2C8) with ~10 times higher affinity compared to PPARα, we postulated that fenofibrate inhibits pathological angiogenesis and protects against retinopathy in part through through CYP2C inhibition as well as PPARα activation. In this study we find CYP2C inhibition with fenofibrate suppresses retinopathy.

Methods : The mouse oxygen-induced retinopathy (OIR) model was used to investigate in vivo retinal neovascularization. Levels of CYP2C8 metabolites in plasma were determined by liquid chromatography and tandem mass spectroscopy. The anti-angiogenic role of fenofibrate and regulation of endothelial cell behaviors were evaluated in an ex vivo aortic ring sprouting assay, and endothelial cell tubule formation and migration assays in vitro.

Results : Fenofibrate inhibits neovascularization in both wild-type and PPARα knock-out mice, suggesting that fenofibrate inhibits pathological angiogenesis in part through a PPARα-independent pathway in addition to its well-known PPARα agonist role. Fenofibrate suppresses neovascularization without PPARα activation in Tie2-driven CYP2C8 over-expressing mice. Fenofibric acid, the bioactive metabolite of fenofibrate, inhibits aortic ring sprouting, endothelial cell tubule formation and migration; CYP2C8 metabolites rescue its inhibitory effects.

Conclusions : Fenofibrate suppresses retinal pathologic neovascularization in part via CYP2C inhibition. Cyp2C inhibition may be a viable approach for inhibition of proliferative retinopathy and other diseases with pathological angiogenesis.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×